Evidence-based cannabis information for athletes, coaches and sports medicine Peer-reviewed citations · League policies tracked · No product sales

Editorial Standards — CannabisForAthletes.org

Evidence hierarchy (peer-reviewed RCTs, NASEM, named clinicians), how we flag emerging research, how we treat league communications, and how we update pages when CBA terms or WADA Prohibited Lists change.

Evidence Hierarchy

Not all evidence is equal. We prioritize sources in this order:

  1. Peer-reviewed randomized controlled trials (RCTs) in athlete or athlete-adjacent populations — Sports Medicine, Sports Medicine - Open, Medicine & Science in Sports & Exercise, British Journal of Sports Medicine, JAMA Internal Medicine, Cannabis & Cannabinoid Research, Journal of Functional Morphology and Kinesiology.
  2. Systematic reviews and scoping reviews — the McCartney et al. 2020 CBD-and-athletes review, the Burr & Cheung 2021 GSSI Sports Science Exchange (industry-funded; we note the funding context), Lisano et al. 2019/2020.
  3. Official league CBA texts and CSMAS documents — the binding text governs over reporting, even from reputable outlets. We cite the NBA-NBPA April 26, 2023 CBA, the NFL-NFLPA March 2020 CBA and December 6, 2024 modification, and CSMAS recommendations directly.
  4. WADA / USADA / IOC official documents — the 2026 Prohibited List, USADA's Cannabis: A Reasoned Approach (April 2022), WADA Executive Committee press releases dated September 23, 2022 and September 22, 2023, and ISTUE 2026.
  5. Named clinicians and institutional research programs — Dr. Kevin Hill (Beth Israel Deaconess / Harvard), Dr. Mark Wallace and Dr. Thomas Marcotte (UC San Diego CMCR), Dr. Patrick Neary (Regina), Dr. Sue Sisley, Dr. Marcel Bonn-Miller, Dr. Donald Abrams, Dr. Orrin Devinsky (NYU Langone).
  6. Observational studies, case reports, and journalism of record — useful for trends and context; we note these limitations when citing.

Evidence Badges

Throughout this site, you will see badges next to specific claims. Tiers:

  • Strong evidence — Conclusive or substantial evidence from multiple high-quality studies. Example: cannabis is not ergogenic (multiple RCTs and the Burr-Cheung 2021 review).
  • Moderate evidence — Limited but consistent evidence. Example: 150-600 mg CBD reduces subjective anxiety in stress-inducing contexts (McCartney 2020).
  • Limited evidence — Small studies or mixed results. Example: CBD for DOMS — Hatchett 2020, Cochrane 2021, Isenmann 2024 report mixed signals on muscle-damage markers.
  • ⚠️ Emerging — Preclinical or single-trial evidence only. We flag with the warning symbol to prevent overreliance.

League-Policy Badges

For league-policy pages, we add a status badge:

  • Removed from list — cannabis removed from the prohibited list (NBA 2023, MLB 2019, NCAA D-I postseason 2024).
  • Tested, fines only — still tested with reduced penalties (NFL post-2024, NHL informational, WNBA).
  • Prohibited in-competition — still prohibited in-competition (WADA, IOC, IPC, MLS).
  • Medical TUE pathway — medical TUE pathway exists but is rarely granted (WADA ISTUE).

How We Handle Emerging Research

Cannabis-and-athlete research is evolving rapidly — the NFL Joint Pain Management Committee research portfolio alone is producing new clinical data on a quarterly cadence. We include emerging research when it is relevant, but we always:

  • Flag it with the ⚠️ Emerging badge.
  • Identify whether the study was preclinical, an athlete pilot, or a randomized trial.
  • Note sample size, study design, and funding source.
  • State explicitly when a finding has not been confirmed in rigorous trials.
  • Avoid presenting preclinical results as treatment recommendations.

How Pages Are Updated When CBA Terms or Prohibited Lists Change

Cannabis policy is one of the most actively-changing areas in sports law. Triggers that prompt a page update:

  • WADA Prohibited List annual update (Executive Committee approves in September; effective January 1). The 2026 list took effect January 1, 2026; the 2027 list cycle is the next inflection point.
  • League CBA negotiations and modifications — the NFL-NFLPA December 6, 2024 modification raised the THC threshold to 350 ng/mL and replaced game-check fines; the WNBA 2026+ CBA renegotiation is the next-most-watched.
  • NCAA CSMAS or Council action — the June 25, 2024 D-I removal; pending D-II/III adoption.
  • State athletic commission rule changes — the NSAC July 2021 and Florida May 2021 reforms.
  • Major federal-law changes — particularly Public Law 119-37 § 781 (effective November 12, 2026) and Executive Order 14370 (December 18, 2025).
  • New peer-reviewed athlete-specific research — e.g., the Sahinovic et al. 2025 randomized trial of 300 mg CBD before a 2-mile time trial.

We do not silently change content. Significant updates are noted on the page. If you believe a claim on this site is inaccurate, outdated, or inadequately sourced, see contact.